Emcure knocked by the FDA for sterility issues after injectable drug recall

facepalm upset mistake (Pixabay / mamamayerle)
Emcure Pharmaceuticals was knocked once again by the FDA for sterility issues at its India-based plant. (Pixabay)

Emcure Pharmaceuticals has had its share of run-ins with the FDA in the past over the sterility of one of its Indian manufacturing plants. Now, it can notch one more black mark on its belt.

The FDA issued Emcure a warning letter earlier this month after investigators said the generic drugmaker did not properly investigate how microbial growth made its way into batches of injectable infection fighter amikacin sulfate and schizophrenia drug prochlorperazine edisylate.

After an inspection in February, investigators said the likely root cause of the failure was a lab error but that Emcure didn’t have the correct procedures in place to identify the problem.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

Wednesday, July 8, 2020 | 11am EST / 8am PST

This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.

“According to your sterility failure investigations, the most probable root cause for both events was laboratory error,” investigators wrote. “Your firm’s investigations substantially addressed the potential for microbial contamination during sterility testing, but deemphasized potential manufacturing causes.”

RELATED: Emcure injected schizophrenia drug recalled after contamination detected

In late May, Heritage Pharmaceuticals, which distributes both Emcure drugs in the U.S., issued a voluntary recall of some sublots after microbial growth was found in unreleased supplies of the two products.

The East Brunswick, New Jersey-based distributor warned that patients injected with either of the drugs could get site-specific or even systemic infections that could lead to hospitalization and death.

The FDA provided a laundry list of improvements for Emcure, saying the voluntary recall didn’t go far enough to address deficiencies at the drugmaker’s Maharasthra, India, plant. Among the changes the FDA requested was a third-party review of Emcure’s inspection records and sterility test methods.

Most troubling for Emcure is that the most recent FDA warning letter was not the first time the agency has cited its plant for sterility problems.

In March 2016, the FDA issued another letter to Emcure citing microbial growth in sublots of two of their injectable products and a lack of sterile facilities. In one instance, the investigators said an “operator placed a cup on the floor … to collect water from a unit (and) used the cup contents to wet the mechanical assembly in the piston drive.”

Suggested Articles

Novartis and Civica Rx are patterning up to shore up supply of six key generic injectables used in acute care settings in hospitals.

EU health commissioner Stella Kyriakides reportedly spoke with Gilead execs to iron out a deal to secure remdesivir supply for 16 EU countries.

Under a $1.6 billion deal with the U.S. government, Novavax has pledged to start producing 100 million doses of a COVID-19 vaccine later this year.